Brouwers Barbara, Dalmasso Bruna, Hatse Sigrid, Laenen Annouschka, Kenis Cindy, Swerts Evalien, Neven Patrick, Smeets Ann, Schöffski Patrick, Wildiers Hans
Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, and Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.
Department of Internal Medicine, Istituto di Ricerca a Carattere Clinico e Scientifico (IRCCS), Azienda Ospedaliera Universitaria (AOU) San Martino Istituto Nazionale Tumori (IST), Genoa, Italy.
Aging (Albany NY). 2015 May;7(5):319-33. doi: 10.18632/aging.100745.
Older cancer patients are a highly heterogeneous population in terms of global health and physiological reserves, and it is often difficult to determine the best treatment. Moreover, clinical tools currently used to assess global health require dedicated time and lack a standardized end score. Circulating markers of biological age and/or fitness could complement or partially substitute the existing screening tools. In this study we explored the relationship of potential ageing/frailty biomarkers with age and clinical frailty. On a population of 82 young and 162 older non-metastatic breast cancer patients, we measured mean leukocyte telomere length and plasma levels of interleukin-6 (IL-6), regulated upon activation, normal T cell expressed and secreted (RANTES), monocyte chemotactic protein 1 (MCP-1), insulin-like growth factor 1 (IGF-1). We also developed a new tool to summarize clinical frailty, designated Leuven Oncogeriatric Frailty Score (LOFS), by integrating GA results in a single, semi-continuous score. LOFS' median score was 8, on a scale from 0=frail to 10=fit. IL-6 levels were associated with chronological age in both groups and with clinical frailty in older breast cancer patients, whereas telomere length, IGF-1 and MCP-1 only correlated with age. Plasma IL-6 should be further explored as frailty biomarker in cancer patients.
老年癌症患者在全球健康和生理储备方面是一个高度异质的群体，通常很难确定最佳治疗方案。此外，目前用于评估全球健康的临床工具需要专门的时间，并且缺乏标准化的最终评分。生物年龄和/或健康状况的循环标志物可以补充或部分替代现有的筛查工具。在本研究中，我们探讨了潜在的衰老/虚弱生物标志物与年龄和临床虚弱之间的关系。在82名年轻和162名老年非转移性乳腺癌患者中，我们测量了平均白细胞端粒长度以及白细胞介素-6（IL-6）、活化后正常T细胞表达和分泌调节因子（RANTES）、单核细胞趋化蛋白1（MCP-1）、胰岛素样生长因子1（IGF-1）的血浆水平。我们还开发了一种新工具来总结临床虚弱情况，通过将GA结果整合为一个单一的半连续评分，命名为鲁汶肿瘤老年虚弱评分（LOFS）。LOFS的中位数评分为8分，范围从0=虚弱到10=健康。两组患者的IL-6水平均与实际年龄相关，在老年乳腺癌患者中还与临床虚弱相关，而端粒长度、IGF-1和MCP-1仅与年龄相关。血浆IL-6应作为癌症患者虚弱生物标志物进一步研究。
